

# HCC-UK 2021 Virtual Conference

## Thursday 18th March-Friday 19th March 2021

### Thursday 18th March 2021 - HCC-UK Research Focus

- 1300-1308 Welcome - *Dr Aileen Marshall - HCC-UK Chair and Consultant Hepatologist, Royal Free London NHS Foundation Trust*
- 1310-1340 **Sponsored session – Roche**  
Who should be considered for 1L systemic combination treatment for advanced or unresectable HCC? - *Dr Tim Cross and Dr Paul Ross*
- 1345-1405 **HCC-UK Basic Science session**  
*Chairs: Dr Matt Hoare, Dr Shish Shetty, Dr Tom Bird*
- 1345-1355 Update CRUK HUNTER Accelerator - *Dr Helen Reeves, Professor of Liver Cancer Newcastle University*
- 1355-1405 Update CRUK DELIVER - *Dr Ellie Barnes, Oxford*
- 1410-1455 **Early Detection**
- 1410-1440 Cell-free TAPS provides multi-dimensional information for early HCC detection - *Dr Chunxiao Song, Principle Investigator, University of Oxford and Chemical Epigenetics Group Lead, Ludwig Institute for Cancer Research*
- 1440-1455 **Basic Science abstract**  
TIAM1, a potential synthetic lethal gene and candidate therapeutic target for hepatocellular carcinoma – *Gordon Strathdee, Biosciences Institute, Newcastle University, Newcastle Upon Tyne*
- 1455-1510 **Tea/Coffee break and poster viewing**
- 1510-1555 **Preclinical Modelling**
- 1510-1540 Clinically relevant models for IO therapies- *Dr Tom Bird, Honorary Consultant Hepatologist, Edinburgh University and Senior Lecturer, CRUK Beatson Institute Glasgow.*
- 1540-1555 **Basic science abstract**  
SULF2 – a potential driver of immune exhaustion in hepatocellular carcinoma - *Dr Ruchi Shukla, Newcastle University Centre For Cancer, Biosciences Institute*



1600-1630 **Sponsored session – Eisai**

*Chair: Prof Rob Duncombe, Director of Pharmacy, The Christie*

Optimising remote consultations – a new era of patient care - *Dr Paul Ross, Kings College Hospital and Donna O’Sullivan, CNS, Royal Free Hospital*

1630-1645 **Tea/Coffee break and poster viewing**

1632-1800

**Nursing Session**

1645-1800 **Novel Immunomodulatory**

1632-1647

Welcome and introductions - *Sarah Selemani, Hcc Cns, Kings College Hospital*

**Therapeutic targets**

1645-1715 Novel immunomodulatory targets and predictors of response to Nivolumab’- *Dr Shilpa Chokshi, Acting Director and Chief Scientific Officer, Institute of Hepatology, and Honorary Reader in Hepatology, King’s College London*

1647-1702

From DGH to tertiary referral - the pathway from the UGI CNS experience - *Anita Ivimy, Eastbourne Hospital*

1715-1730 **Basic Science abstract**

1702 - 1717

Managing IO side effects and work up in HCC - the CNS role – *Emma Ainsworth, Newcastle NHS Trust*

Harnessing liver-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma – *Dr Nekisa Zakeri, University College London*

1717-1800

Q&A and networking

1730-1800 ‘Scavenger receptors in the tumour microenvironment’- *Dr Shish Shetty, Cancer Research UK Advanced Clinician Scientist and Principal Investigator in the Centre for Liver and Gastrointestinal Research, University of Birmingham*

1800 **Wrap-up - Dr Matt Hoare**



## Friday 19th March 2021 - Developments in HCC in 2020 - Clinical day

- 1230-1238 Welcome to day two - *Dr Aileen Marshall, HCC-UK Chair and Consultant Hepatologist, Royal Free London NHS Foundation Trust*
- 1240-1310 **Sponsored session – Sirtex**  
Advances in SIR-Spheres® therapy for HCC
- Latest update for the place of SIRT in HCC - *Dr Abid Suddle–Institute of Liver Studies, King's College Hospital (London)*
- Evolving the treatment of HCC with SIR-Spheres – *Dr Damian Mullan & Dr Pavan Najran–Radiology, The Christie Hospital (Manchester)*
- 1315-1415 **HCC MDT**  
**MDT**
- Hepatology - *Dr Vicky Snowdon, Consultant Hepatologist, Addenbrooke's Hospital*
- Surgeon – *Miss Anya Adair - Transplant/HPB Surgeon, Edinburgh Royal Infirmary and Clinical Lead for the Scottish HPB Cancer Network.*
- IR – *Dr Teik Choon See, Consultant Interventional radiologist and clinical lead for Radiology, Addenbrookes*
- Oncologist – *Professor Tim Meyer, Professor of Experimental Cancer Medicine, University College London*
- Case one - *Dr Mary Cannon, Consultant Hepatologist and Dr Abid Suddle Consultant Hepatologist, Kings College London*
- Case two - *Professor Dan Palmer, Molecular & Clinical Cancer Medicine, University of Liverpool*
- 1420-1520 **Updates in HCC management (1)**  
*Chairs: Professor Tim Meyer and Dr Vicky Snowdon*
- 1420-1445 Results of Down-staging trial – *Dr Aileen Marshall, HCC-UK Chair and Consultant Hepatologist, Royal Free London NHS Foundation Trust*
- 1445-1520 Updates in Systemic Therapy - What 2021 holds for us - *Dr Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust, Manchester, UK.*



1520-1535 **Tea/Coffee break and poster viewing**

1535-1725 **Updates in HCC management (2)**

*Chairs: Dr Tim Cross and Dr Aileen Marshall*

1535-1615 Covid and HCC - *Dr Maria Reig - Head of Liver Oncology Unit, Barcelona clinic liver cancer*

1615-1715 **Free Clinical Papers**

1615-1630 Developing a national clinical nurse specialist network for patients with hepatocellular carcinoma in Scotland – *Dr Thomas Drake, University of Edinburgh*

1630-1645 A review of adverse events associated with the use of Atezolizumab and Bevacizumab for the treatment of Hepatocellular Carcinoma on the Early Access to Medicines Scheme (EAMS) – *Dr Stuart Brown, Royal Free London NHS Foundation Trust*

1645-1700 Patients with hepatocellular carcinoma have higher risk aMAP scores up to 5 years before diagnosis – *Dr Benjamin Giles, Portsmouth Hospitals University NHS Trust*

1700-1715 Suitability for treatment with atezolizumab and bevacizumab in patients referred with a diagnosis of advanced HCC – *Dr Dinakshi Shah, The Christie NHS Foundation Trust*

1715-1725 Final remarks and close – *Dr Aileen Marshall, HCC-UK Chair and Consultant Hepatologist, Royal Free London NHS Foundation Trust*

#### Gold Sponsors



#### Silver Sponsors



Thank you for our conference sponsors, who have had no input into the agenda, with the exception of the sponsored symposium sessions, for which the sponsoring companies are fully responsible.